Atlas Trials

Evaluating a Pharmacogenetic Testing Panel in Patients Suspected to be at Increased Risk for Pharmacogenetics-related AEs While Receiving Fluoropyrimidine or Irinotecan Therapy

Clinical trial NCT05583422 · COMPLETED

Trial details

NCT number
NCT05583422
Sponsor
University of Michigan Rogel Cancer Center
Status
COMPLETED
Study type
OBSERVATIONAL
Cancer
Start date
2023-08-18
Primary completion
2024-06-17
Enrollment
16

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.